Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of lenalidomide when given
together with temsirolimus and to see how well it works in treating patients with Hodgkin
lymphoma or non-Hodgkin lymphoma that has come back after a period of improvement or is not
responding to treatment. Biological therapies, such as lenalidomide, may stimulate the immune
system in different ways and stop cancer cells from growing. Lenalidomide may also stop the
growth of Hodgkin lymphoma or non-Hodgkin lymphoma by blocking blood flow to the cancer.
Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving lenalidomide together with temsirolimus may kill more cancer cells.